Alexion Pharmaceuticals
3-year average:
Revenue Growth: 43%
Profit Growth: 34%
Total Return: 69%
Revenue Growth: 43%
Profit Growth: 34%
Total Return: 69%
This biopharmaceutical company is
focused on treating two severe and ultra-rare disorders. Its lead
product, Soliris, is the only drug approved for patients with an
extremely rare and life-threatening blood disease referred to as PNH
(paroxysmal nocturnal hemoglobinuria). Alexion reported $274 million
worth of second-quarter sales of Soliris, up 48% from the same period
last year. The company credited the growth to increasing numbers of
patients being treated with the drug globally. It follows Soliris's
approval in the U.S. and European Union late last year as the first and
only treatment for patients with an ultra-rare genetic disease known as
Atypical Hemolytic Uremic Syndrome (aHUS). -- N.S.
No comments:
Post a Comment